ADARx Pharmaceuticals announced the appointment of Dr. Mary Tagliaferri to its Board of Directors, highlighting her extensive experience in clinical development and drug strategy across biotechnology organizations.

Biotech company Nektar Therapeutics reported Q2 earnings with lower revenue compared to last year, but received positive market reaction and FDA Fast Track designation for an investigational drug targeting alopecia areata.

Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.

Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. See why NKTR stock is a Hold.

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin. Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. Here are some other stocks moving in today's mid-day session. Gainers BitFuFu Inc. (NASDAQ: FUFU) shares jumped 107% to $13.20 amid volatility following the company's recent business combination with Arisz Acquisition Corp and listing on the Nasdaq. Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) climbed 89% to $5.31 after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies. Renalytix Plc (NASDAQ: RNLX) gained 52.8% to $1.5890 after the company announced that it received an unsolicited approach from a publicly listed strategic diagnostics company. Phunware, Inc. (NASDAQ: PHUN) climbed 42.7% to $10.11. Phunware is expected to report fourth-quarter results on March 12, 2024. Ainos, Inc. (NASDAQ: AIMD) gained 39.4% to $1.4650. Jaguar Health, Inc. (NASDAQ: JAGX) shares climbed 38.2% to $0.1223 after surging 50% on Friday. Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 31.6% to $3.83 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial. The E.W. Scripps Company (NASDAQ: SSP) gained 31.3% to $4.94. E.W. Scripps Director Charles L. Barmonde acquired a total of 10,500 shares an average price of $4.28. Helius Medical Technologies, Inc. (NASDAQ: HSDT) climbed 30% to $5.91. Helius Medical Technologies announced it secured HCPCS codes for portable neuromodulation stimulator mouthpiece and controller. Kineta, Inc. (NASDAQ: KA) gained 27% to $1.14. Kineta recently announced a restructuring and the exploration of strategic alternatives. BigBear.ai Holdings, Inc. (NYSE: BBAI) rose 25% to $4.3472. Critical Metals Corp. (NASDAQ: CRML) gained 24.4% to $12.44. Ocean Biomedical, Inc. (NASDAQ: OCEA) gained 22% to $2.44. Reliance Global Group, Inc. (NASDAQ: RELI) rose 21.7% to $0.6299 after gaining 11% on Friday. Akero Therapeutics, Inc. (NASDAQ: AKRO) ...

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.